Skip to content
Gyre Therapeutics
Primary Menu
About
Overview
Management Team
Board of Directors
Science
Overview
Hydronidone
MASH
Other Disease Areas
Publications
Investors
Press Releases
Events and Presentations
Events
Presentations
Scientific Presentations and Publications
Financials & Filings
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Leadership Team
Board of Directors
Committee Composition
Investor FAQ
Contact
ISTH 2019 – Quality of Life of Hemophilia Patients with Inhibitors – Opportunities for Improvement
Post navigation
Previous:
AAV Based Hemophilia B Gene Therapy in Mice Using FIX-CB2679d-GT
Next:
ISTH 2019 – Phase 2/3 Trial of Subcutaneous Engineered FVIIa Marzeptacog Alfa (Activated) in Hemophilia A or B with Inhibitors: Efficacy, Safety and Pharmacokinetics
X
Previous
Next
